טוען...
Advances in antibody–drug conjugates: a new era of targeted cancer therapy
Antibody–drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing. In the initial phase of their development, two ADCs, Mylotarg®, and Adcetris® were approved by the...
שמור ב:
| הוצא לאור ב: | Drug Discov Today |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6944323/ https://ncbi.nlm.nih.gov/pubmed/28627385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2017.05.011 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|